Marwan Ghabril1, Jiezhun Gu2, Lindsay Yoder1, Laura Corbito1, Amit Ringel3, Christian D Beyer3, Raj Vuppalanchi1, Huiman Barnhart2, Paul H Hayashi2, Naga Chalasani4. 1. Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 3. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina. 4. Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana. Electronic address: nchalasa@iu.edu.
Abstract
BACKGROUND & AIMS: Patients with drug-induced liver injury (DILI) frequently have comorbid conditions, but the effects of non-liver comorbidities on outcomes are not well understood. We investigated the association between comorbidity burden and outcomes of patients with DILI, and developed and validated a model to calculate risk of death within 6 months. METHODS: A multiple logistic regression model identified variables independently associated with death within 6 months of presenting with suspected DILI (6-month mortality) for 306 patients enrolled in the Drug-Induced Liver Injury Network prospective study at Indiana University (discovery cohort). The model was validated using data from 247 patients with suspected DILI enrolled in the same study at the University of North Carolina (validation cohort). Medical comorbidity burden was calculated using the Charlson Comorbidity Index-patients with scores higher than 2 were considered to have significant comorbidities. RESULTS: Six-month mortality was 8.5% in the discovery cohort and 4.5% in the validation cohort. In the discovery cohort, significant comorbidities (odds ratio, 5.4; 95% confidence interval [CI], 2.1-13.8), Model for End-Stage Liver Disease score (odds ratio, 1.11; 95% CI, 1.04-1.17), and serum level of albumin at presentation (odds ratio, 0.39; 95% CI, 0.2-0.76) were independently associated with 6-month mortality. A model based on these 3 variables identified patients who died within 6 months, with c-statistic values of 0.89 (95% CI, 0.86-0.94) in the discovery cohort and 0.91 (95% CI, 0.83-0.99) in the validation cohort. We developed a web-based calculator for use in the clinic to determine risk of death within 6 months for patients with suspected DILI. CONCLUSIONS: We developed and validated a model based on comorbidity burden, Model for End-Stage Liver Disease score, and serum level of albumin that predicts 6-month mortality in patients with suspected DILI.
BACKGROUND & AIMS:Patients with drug-induced liver injury (DILI) frequently have comorbid conditions, but the effects of non-liver comorbidities on outcomes are not well understood. We investigated the association between comorbidity burden and outcomes of patients with DILI, and developed and validated a model to calculate risk of death within 6 months. METHODS: A multiple logistic regression model identified variables independently associated with death within 6 months of presenting with suspected DILI (6-month mortality) for 306 patients enrolled in the Drug-Induced Liver Injury Network prospective study at Indiana University (discovery cohort). The model was validated using data from 247 patients with suspected DILI enrolled in the same study at the University of North Carolina (validation cohort). Medical comorbidity burden was calculated using the Charlson Comorbidity Index-patients with scores higher than 2 were considered to have significant comorbidities. RESULTS: Six-month mortality was 8.5% in the discovery cohort and 4.5% in the validation cohort. In the discovery cohort, significant comorbidities (odds ratio, 5.4; 95% confidence interval [CI], 2.1-13.8), Model for End-Stage Liver Disease score (odds ratio, 1.11; 95% CI, 1.04-1.17), and serum level of albumin at presentation (odds ratio, 0.39; 95% CI, 0.2-0.76) were independently associated with 6-month mortality. A model based on these 3 variables identified patients who died within 6 months, with c-statistic values of 0.89 (95% CI, 0.86-0.94) in the discovery cohort and 0.91 (95% CI, 0.83-0.99) in the validation cohort. We developed a web-based calculator for use in the clinic to determine risk of death within 6 months for patients with suspected DILI. CONCLUSIONS: We developed and validated a model based on comorbidity burden, Model for End-Stage Liver Disease score, and serum level of albumin that predicts 6-month mortality in patients with suspected DILI.
Authors: Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar Journal: Gastroenterology Date: 2014-03-27 Impact factor: 22.682
Authors: Manoch Rattanasompattikul; Usama Feroze; Miklos Z Molnar; Ramanath Dukkipati; Csaba P Kovesdy; Allen R Nissenson; Keith C Norris; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Int Urol Nephrol Date: 2011-11-30 Impact factor: 2.370
Authors: Paul H Hayashi; Don C Rockey; Robert J Fontana; Hans L Tillmann; Neil Kaplowitz; Huiman X Barnhart; Jiezhan Gu; Naga P Chalasani; K Rajender Reddy; Averell H Sherker; Jay H Hoofnagle Journal: Hepatology Date: 2017-08-26 Impact factor: 17.425
Authors: Naga Chalasani; Herbert L Bonkovsky; Robert Fontana; William Lee; Andrew Stolz; Jayant Talwalkar; K Rajendar Reddy; Paul B Watkins; Victor Navarro; Huiman Barnhart; Jiezhun Gu; Jose Serrano Journal: Gastroenterology Date: 2015-03-06 Impact factor: 22.682
Authors: A Canbay; C Jochum; L P Bechmann; S Festag; R K Gieseler; Z Yüksel; P Lütkes; F H Saner; A Paul; G Gerken Journal: Z Gastroenterol Date: 2009-09-11 Impact factor: 2.000
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins Journal: Am J Gastroenterol Date: 2015-09-08 Impact factor: 10.864
Authors: Karim S Ladha; Kevin Zhao; Sadeq A Quraishi; Tobias Kurth; Matthias Eikermann; Haytham M A Kaafarani; Eric N Klein; Raghu Seethala; Jarone Lee Journal: BMJ Open Date: 2015-09-08 Impact factor: 2.692